092780.KS DND Pharmatech Loading...

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
02:29
Jul 01
Park Ji-hoon Director, Asset Management Consulting Dept., NH Investment … 3PRO TV (삼프로TV)
DND Pharmatech out-licensing deal imminent.
DND Pharmatech is the biotech most intensely eyed for a near-term out-licensing deal. The market is eagerly anticipating a technology transfer agreement, and the company has built a strongly positive narrative. In an environment where Korean biotech needs license-out catalysts, DND stands at the center of expectation.
092780.KS
MED

About 092780.KS Analyst Coverage

Buzzberg tracks 092780.KS (DND Pharmatech) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Park Ji-hoon.